- |||||||||| Leukine (sargramostim) / Partner Therap
Trial completion, Combination therapy: Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer (clinicaltrials.gov) - Jun 25, 2013 P1, N=18, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013 P1, N=23, Terminated, N=99 --> 147 Active, not recruiting --> Terminated; Replaced by another study
- |||||||||| Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013 P1, N=23, Terminated, Active, not recruiting --> Terminated; Replaced by another study N=45 --> 23
- |||||||||| Campath (alemtuzumab) / Sanofi, Rituxan (rituximab) / Roche
Enrollment closed: Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - Apr 7, 2013 P2, N=42, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Leukine (sargramostim) / Partner Therap, NeuVax (nelipepimut-S) / Dr. Reddy's, Herceptin (trastuzumab) / Roche
Enrollment open: Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax (clinicaltrials.gov) - Feb 13, 2013 P2, N=300, Recruiting, Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||||||| Trial termination: p53 Vaccine for Ovarian Cancer (clinicaltrials.gov) - Jan 29, 2013
P2, N=21, Terminated, Active, not recruiting --> Terminated; Departure of PI Completed --> Terminated
|